Abstract
Purpose
To evaluate the influence of smoking on comorbidity, treatment, visual and general outcome in patients with scleritis.
Methods
The smoking habits of 103 patients with a diagnosis of episcleritis or scleritis were evaluated. These patients were treated by one ruling protocol at the Leiden University Medical Center between 1997 and 2000. Medical records of each patient were evaluated in detail. Data on possible factors concerning smoking were collected by postal questionnaire.
Results
Of all 103 patients diagnosed with either episcleritis or scleritis, 41 (39.8%) were smoking during treatment of the scleral inflammation. In total, 19 patients (18.4%) had a smoking history while 43 (41.7%) patients have never smoked. The response to anyof the given medications could be delayed by at least 4 weeks in many smoking patients (odds ratio (OR) 5.4 [95% confidence interval 1.9–15.5]), particularly those with posterior scleritis. Smoking patients above the age of 48 years were even more likely to respond belatedly to any given therapy (OR 6.6 [2.1–20.7]). However, having a smoking history did not delay the response. Furthermore, smoking did not worsen the visual prognosis and was not associated with additional recurrences or ocular complications after successful treatment.
Conclusions
Although scleritis patients who smoked during treatment eventually responded, there was frequently over a month's delay before the medication became effective when compared to nonsmokers. This was irrespective of the type of disease or given therapy. As a consequence, smokers required more intensive therapy than those who did not smoke.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Watson PG, Hayreh SS . Scleritis and episcleritis. Br J Ophthalmol 1976; 60: 163–191.
Tuft SJ, Watson PG . Progression of scleral disease. Ophthalmology 1991; 98: 467–471.
Watson P . In: Tasman W, Jaeger EA (eds). Diseases of the sclera and episclera. Duane's Clinical Ophthalmology. Chapter 23. Lippincott Williams & Wilkins Publishers: Philadelphia, PA, 2002.
Schein JR . Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995; 29: 1139–1148.
Yearly report STIVORO 2002. Look at: http://www.stivoro.nl., 2002.
Criswell LA, Merlino LA, Cerhan JR, Mikuls TR, Mudano AS, Burma M . Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Med 2002; 112: 465–471.
Ghadirian P, Dadgostar B, Azani R, Maisonneuve P . A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can J Public Health 2001; 92: 281–285.
Murin S, Bilello KS, Matthay R . Other smoking-affected pulmonary diseases. Clin Chest Med 2000; 21: 121–137,ix.
Bridger S, Lee JC, Bjarnason I, Jones JE, Macpherson AJ . In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut 2002; 51: 21–25.
Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F . More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 1989; 12: 733–737.
Prummel MF, Wiersinga WM . Smoking and risk of Graves' disease. JAMA 1993; 269: 479–482.
Wiersinga WM, Prummel MF . Graves' ophthalmopathy: a rational approach to treatment. Trends Endocrinol Metab 2002; 13: 280–287.
Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP . Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998; 129: 632–635.
Wiersinga WM, Prummel MF . An evidence-based approach to the treatment of Graves' ophthalmopathy. Endocrinol Metab Clin North Am 2000; 29: 297–319,vi–vii.
Nieuwenhuizen J, Watson PG, Jager MJ, Emmanouilidis-van der Spek K, Keunen JE . The value of combining anterior segment fluorescein angiography with indocyanine green angiography in scleral inflammation. Ophthalmology 2003; 110: 1653–1666.
Grygiel JJ, Birkett DJ . Cigarette smoking and theophylline clearance and metabolism. Clin Pharmacol Ther 1981; 30: 491–496.
Nemeroff CB, DeVane CL, Pollock BG . Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153: 311–320.
Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R . Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58: 399–403.
Vinarova E, Vinar O, Kalvach Z . Smokers need higher doses of neuroleptic drugs. Biol Psychiatry 1984; 19: 1265–1268.
Goff DC, Henderson DC, Amico E . Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149: 1189–1194.
Hansten PD, Horn JR, Koda-Kimble MA, Young LYE . Effects of Cigarette Smoking on Drug Actions. Applied Therapeutics Inc.: Vancouver, 1993.
Vestal RE, Wood AJ . Influence of age and smoking on drug kinetics in man: studies using model compounds. Clin Pharmacokinet 1980; 5: 309–319.
Madsbad S, McNair P, Christensen MS, Christiansen C, Faber OK, Binder C . Influence of smoking on insulin requirement and metabolic status in diabetes mellitus. Diabetes Care 1980; 3: 41–43.
Clinical depression of the central nervous system due to diazepam and chlordiazepoxide in relation to cigarette smoking and age. N Engl J Med 1973; 288: 277–280.
Miller RR . Effects of smoking on drug action. Clin Pharmacol Ther 1977; 22: 749–756.
Dollery C, Brennan PJ . The Medical Research Council Hypertension Trial: the smoking patient. Am Heart J 1988; 115: 276–281.
Deanfield J, Wright C, Krikler S, Ribeiro P, Fox K . Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. N Engl J Med 1984; 310: 951–954.
Holt PG . Immune and inflammatory function in cigarette smokers. Thorax 1987; 42: 241–249.
Holt PG, Keast D . Environmentally induced changes in immunological function: acute and chronic effects of inhalation of tobacco smoke and other atmospheric contaminants in man and experimental animals. Bacteriol Rev 1977; 41: 205–216.
Sopori M . Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2: 372–377.
Barbour SE, Nakashima K, Zhang JB, Tangada S, Hahn CL, Schenkein HA . Tobacco and smoking: environmental factors that modify the host response (immune system) and have an impact on periodontal health. Crit Rev Oral Biol Med 1997; 8: 437–460.
Albano SA, Santana-Sahagun E, Weisman MH . Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum 2001; 31: 146–159.
Soy M, Erken E, Konca K, Ozbek S . Smoking and Behcet's disease. Clin Rheumatol 2000; 19: 508–509.
Mattoli S, Kleimberg J, Stacey MA, Bellini A, Sun G, Marini M . The role of CD8+ Th2 lymphocytes in the development of smoking-related lung damage. Biochem Biophys Res Commun 1997; 239: 146–149.
Reckner Olsson A, Skogh T, Wingren G . Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 934–939.
Author information
Authors and Affiliations
Corresponding author
Additional information
Data in this paper have not been presented in any meeting.
Financial support: None.
Commercial interest: None.
Rights and permissions
About this article
Cite this article
Boonman, Z., de Keizer, R. & Watson, P. Smoking delays the response to treatment in episcleritis and scleritis. Eye 19, 949–955 (2005). https://doi.org/10.1038/sj.eye.6701731
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.eye.6701731
Keywords
This article is cited by
-
Smoking’s Effects on Ocular Inflammatory Disorders
Current Allergy and Asthma Reports (2011)
-
Comment on ‘smoking delays the response to treatment in episcleritis and scleritis’
Eye (2006)
